Our vision is to offer affordable, practical and effective vaccines on-demand, which are suited to low resource environments, disproportionately affected by pandemics. These vaccines will be used to create a clinical grade international vaccine repository that will act as a first line of defence in the case of existing and newly emerging infectious disease outbreaks.
- Emergex Signs an R&D Agreement with IMCB to Develop a Vaccine for the Emerging Threat of Hand, Foot & Mouth Disease 27 June 2019
- Dr. Athanasios Papadopoulos joins Emergex as Chief Medical Officer 27 February 2019
- Emergex Secures State-of-the-art R&D Facility and Hires a Chief Scientific Officer to Drive Development of its Vaccines 18 February 2019